| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 23 | 2025 | 550 | 5.690 |
Why?
|
| Methotrexate | 5 | 2025 | 350 | 2.230 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 193 | 1.880 |
Why?
|
| Antineoplastic Agents | 8 | 2025 | 1825 | 1.620 |
Why?
|
| Cyclopentanes | 2 | 2024 | 21 | 1.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 814 | 1.300 |
Why?
|
| Pyrimidines | 2 | 2024 | 418 | 1.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1342 | 1.250 |
Why?
|
| Neoplasms | 7 | 2025 | 2955 | 1.110 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 304 | 1.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 276 | 1.040 |
Why?
|
| Hepatoblastoma | 3 | 2024 | 183 | 1.030 |
Why?
|
| Child | 42 | 2025 | 25761 | 0.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 1197 | 0.920 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 444 | 0.890 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 56 | 0.850 |
Why?
|
| Child, Preschool | 24 | 2025 | 14732 | 0.820 |
Why?
|
| Pediatrics | 4 | 2022 | 1211 | 0.810 |
Why?
|
| Adolescent | 25 | 2025 | 20535 | 0.760 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1028 | 0.730 |
Why?
|
| Algorithms | 3 | 2025 | 1719 | 0.700 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1381 | 0.690 |
Why?
|
| Legislation, Drug | 1 | 2020 | 9 | 0.690 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 32 | 0.680 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 35 | 0.670 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 58 | 0.660 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 25 | 0.660 |
Why?
|
| Off-Label Use | 2 | 2025 | 28 | 0.650 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 56 | 0.640 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 95 | 0.640 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 89 | 0.640 |
Why?
|
| Orchiectomy | 1 | 2019 | 54 | 0.610 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 19 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 605 | 0.600 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 56 | 0.590 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.590 |
Why?
|
| Neutropenia | 1 | 2020 | 205 | 0.590 |
Why?
|
| Humans | 55 | 2025 | 131924 | 0.580 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 142 | 0.580 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.580 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 127 | 0.580 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 97 | 0.580 |
Why?
|
| Radiotherapy | 1 | 2019 | 145 | 0.580 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.570 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 588 | 0.570 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 131 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2025 | 1304 | 0.560 |
Why?
|
| Quinazolines | 1 | 2019 | 176 | 0.560 |
Why?
|
| Organophosphonates | 1 | 2018 | 21 | 0.560 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 74 | 0.560 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 127 | 0.560 |
Why?
|
| Cytosine | 1 | 2018 | 58 | 0.550 |
Why?
|
| Doxorubicin | 1 | 2019 | 303 | 0.550 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 150 | 0.540 |
Why?
|
| BK Virus | 1 | 2018 | 60 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 149 | 0.540 |
Why?
|
| Hearing Loss | 3 | 2025 | 211 | 0.540 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 164 | 0.540 |
Why?
|
| Cystitis | 1 | 2018 | 51 | 0.530 |
Why?
|
| Bacterial Infections | 1 | 2020 | 323 | 0.530 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 90 | 0.530 |
Why?
|
| Infection Control | 1 | 2018 | 157 | 0.530 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 139 | 0.520 |
Why?
|
| Osteosarcoma | 1 | 2019 | 262 | 0.520 |
Why?
|
| Infant | 17 | 2025 | 13047 | 0.520 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 327 | 0.510 |
Why?
|
| Apoptosis | 2 | 2021 | 1891 | 0.480 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1293 | 0.470 |
Why?
|
| Thoracic Wall | 1 | 2015 | 40 | 0.460 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 295 | 0.460 |
Why?
|
| Female | 29 | 2025 | 70584 | 0.460 |
Why?
|
| Survival Rate | 5 | 2024 | 2186 | 0.460 |
Why?
|
| Male | 26 | 2025 | 64870 | 0.450 |
Why?
|
| Cisplatin | 3 | 2025 | 282 | 0.450 |
Why?
|
| Prognosis | 8 | 2025 | 5007 | 0.450 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 1536 | 0.430 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 196 | 0.430 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17374 | 0.420 |
Why?
|
| Follow-Up Studies | 8 | 2025 | 5408 | 0.410 |
Why?
|
| NEDD8 Protein | 2 | 2024 | 12 | 0.400 |
Why?
|
| Sarcoma | 1 | 2015 | 207 | 0.400 |
Why?
|
| Disease Management | 1 | 2017 | 562 | 0.400 |
Why?
|
| Young Adult | 10 | 2025 | 9952 | 0.390 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1861 | 0.380 |
Why?
|
| Antiviral Agents | 1 | 2018 | 822 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2025 | 1672 | 0.370 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2507 | 0.360 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 68 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1299 | 0.330 |
Why?
|
| Drug Monitoring | 2 | 2025 | 174 | 0.320 |
Why?
|
| Drug Therapy | 1 | 2020 | 87 | 0.310 |
Why?
|
| Proton Therapy | 2 | 2022 | 159 | 0.300 |
Why?
|
| Emergencies | 1 | 2020 | 186 | 0.290 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12991 | 0.280 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 136 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 174 | 0.270 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 160 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 990 | 0.260 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 958 | 0.240 |
Why?
|
| Thiosulfates | 1 | 2025 | 7 | 0.230 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3678 | 0.220 |
Why?
|
| Biopsy | 2 | 2018 | 1284 | 0.220 |
Why?
|
| United States | 6 | 2024 | 11648 | 0.210 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 286 | 0.210 |
Why?
|
| Dexamethasone | 1 | 2025 | 274 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2022 | 244 | 0.200 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 66 | 0.200 |
Why?
|
| Internal Medicine | 1 | 2024 | 155 | 0.190 |
Why?
|
| Tracheostomy | 1 | 2024 | 204 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2022 | 6569 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 37 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2021 | 36 | 0.180 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 6 | 0.180 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 17 | 0.180 |
Why?
|
| Incidence | 3 | 2024 | 3375 | 0.180 |
Why?
|
| MyoD Protein | 1 | 2021 | 24 | 0.180 |
Why?
|
| Radioisotopes | 1 | 2021 | 27 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2022 | 246 | 0.170 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 144 | 0.170 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 54 | 0.170 |
Why?
|
| Government Regulation | 1 | 2020 | 43 | 0.170 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 547 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 170 | 0.160 |
Why?
|
| Animals | 6 | 2022 | 34781 | 0.160 |
Why?
|
| Risk Factors | 3 | 2019 | 10933 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2022 | 356 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 104 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 162 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 749 | 0.160 |
Why?
|
| Medication Errors | 1 | 2021 | 205 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 808 | 0.150 |
Why?
|
| Vincristine | 1 | 2020 | 196 | 0.150 |
Why?
|
| Etoposide | 1 | 2019 | 121 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 183 | 0.150 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 70 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 308 | 0.150 |
Why?
|
| Sodium | 1 | 2020 | 295 | 0.150 |
Why?
|
| Drug Synergism | 1 | 2019 | 234 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2021 | 611 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 333 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 189 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 210 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 247 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 214 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 100 | 0.140 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 33 | 0.140 |
Why?
|
| Tissue Distribution | 1 | 2018 | 380 | 0.140 |
Why?
|
| Gangliosides | 1 | 2018 | 73 | 0.140 |
Why?
|
| Wilms Tumor | 1 | 2019 | 119 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 396 | 0.140 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 108 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 195 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2019 | 291 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 301 | 0.140 |
Why?
|
| Adult | 7 | 2025 | 31536 | 0.140 |
Why?
|
| Mice, Nude | 1 | 2019 | 750 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 188 | 0.130 |
Why?
|
| Mucositis | 1 | 2017 | 21 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 327 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 763 | 0.130 |
Why?
|
| Risk | 1 | 2018 | 761 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 301 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2021 | 608 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 524 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2017 | 321 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1440 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2017 | 147 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 589 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 806 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 985 | 0.120 |
Why?
|
| Acute Disease | 1 | 2018 | 1160 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8542 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2020 | 744 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2443 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 627 | 0.100 |
Why?
|
| Cytokines | 1 | 2018 | 1359 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 408 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2912 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2020 | 4703 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 671 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 652 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2024 | 1247 | 0.070 |
Why?
|
| Mice | 2 | 2021 | 18460 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 553 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 416 | 0.060 |
Why?
|
| Injection, Intratympanic | 1 | 2025 | 2 | 0.060 |
Why?
|
| Costa Rica | 1 | 2025 | 15 | 0.060 |
Why?
|
| Topotecan | 1 | 2025 | 50 | 0.060 |
Why?
|
| Gels | 1 | 2025 | 72 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 252 | 0.050 |
Why?
|
| Aspirin | 1 | 2005 | 220 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 617 | 0.050 |
Why?
|
| Piperidines | 1 | 2025 | 235 | 0.050 |
Why?
|
| Indazoles | 1 | 2022 | 31 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2025 | 428 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 288 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2025 | 332 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 98 | 0.050 |
Why?
|
| Dosage Forms | 1 | 2021 | 9 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 124 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 820 | 0.050 |
Why?
|
| Bays | 1 | 2021 | 7 | 0.050 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 17 | 0.050 |
Why?
|
| Drug Storage | 1 | 2021 | 18 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 147 | 0.050 |
Why?
|
| Pamphlets | 1 | 2021 | 24 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1169 | 0.050 |
Why?
|
| Maternal Age | 1 | 2022 | 139 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2021 | 42 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2021 | 43 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 504 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 230 | 0.040 |
Why?
|
| Nonprescription Drugs | 1 | 2021 | 54 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 178 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2021 | 72 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2005 | 684 | 0.040 |
Why?
|
| SEER Program | 1 | 2022 | 220 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3139 | 0.040 |
Why?
|
| Health Literacy | 1 | 2021 | 78 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 192 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 105 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 120 | 0.040 |
Why?
|
| Language | 1 | 2021 | 224 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 219 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 71 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2019 | 8 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 613 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1458 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 239 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1579 | 0.030 |
Why?
|
| Allergens | 1 | 2019 | 276 | 0.030 |
Why?
|
| Caregivers | 1 | 2021 | 588 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 2850 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 1330 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 1079 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3990 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3627 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1647 | 0.020 |
Why?
|
| Hawaii | 1 | 2012 | 7 | 0.020 |
Why?
|
| Publications | 1 | 2012 | 35 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 103 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 232 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5163 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7543 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6226 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21385 | 0.010 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2005 | 10 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 2005 | 9 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 17 | 0.010 |
Why?
|
| Premedication | 1 | 2005 | 42 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 106 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 316 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28943 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 183 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 547 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 824 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 320 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 804 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1684 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 2696 | 0.010 |
Why?
|